The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Subscribe To Our Newsletter & Stay Updated
